How do we value a cure?

References

• Three hundred aesop’s fables. literally translated from the greek. by george fyler townsend. Internet Available from: www.alibris.com/Three-Hundred-Aesops-Fables-Literally-Translated-from-the-Greek-by-George-Fyler-Townsend-Aesop/book/15973376 [Cited 14 February 2015]
   Google Scholar
• The sale of quack medicines: demand for legislation. Br Med J 1911;1(2625):945
   Google Scholar
• Commissioner O of the. Consumer Updates - Faster, Easier Cures for Hepatitis C. Internet Available from: www.fda.gov/ForConsumers/ConsumerUpdates/ucm405642.htm [Cited 14 February 2015]
   Google Scholar
• Is this how we’ll cure cancer? - Forbes. Internet Available from: www.forbes.com/sites/matthewherper/2014/05/07/is-this-how-well-cure-cancer/ [Cited 14 February 2015]
   Google Scholar
• Sax PE, Sypek A, Berkowitz BK, et al. HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One 2014;9(11):e113031
   Google Scholar
• Kashyap SR, Louis ES, Kirwan JP. Weight loss as a cure for type 2 diabetes? fact or fantasy. Expert Rev Endocrinol Metab 2011;6(4):557-61
   PubMedGoogle Scholar
• Tagliabue E, Campiglio M. ‘Omics’ and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas. Front Oncol 2014;4:334
   Google Scholar
• Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015;35(Suppl 1):71-7
   PubMedGoogle Scholar
• U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C Gilead. Internet Available from: www.gilead.com/news/press-releases/2014/10/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-oncedaily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c [Cited 14 February 2015]
   Google Scholar
• Koretz RL, Lin KW, Ioannidis JPA, Lenzer J. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809
   Google Scholar
• Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med 2008;3(1):1-5
   PubMed Web of Science ®Google Scholar
• Ellsberg D. Risk, Ambiguity and Decision. 1st edition. Routledge; New York, NY: 2001. p. 288
   Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health 2013;16(1):3-13
   PubMed Web of Science ®Google Scholar
• Goldman D, Lakdawalla D, Philipson TJ, Yin W. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ 2010;19(10):1109-16
   PubMed Web of Science ®Google Scholar
• Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY?: Four core issues to resolve. Health Policy 2005;74(1):77-84
   PubMedGoogle Scholar
• Guide to the methods of technology appraisal 2013 the-appraisal-of-the-evidence-and-structured-decision-making Guidance and guidelines NICE. Internet Available from: www.nice.org.uk/article/pmg9/chapter/the-appraisal-of-the-evidence-and-structured-decision-making [Cited 14 February 2015]
   Google Scholar
• Skedgel C, Wailoo A, Akehurst R. Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment. Med Decis Making 2015;35(1):94-105
   Google Scholar
• Diaby V, Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert Rev Pharmacoecon Outcomes Res 2014;14(1):81-99
   PubMed Web of Science ®Google Scholar
• Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health 2012;15(8):1172-81
   PubMed Web of Science ®Google Scholar
• Ubel PA, Spranca MD, Dekay ML, et al. Public preferences for prevention versus cure: what if an ounce of prevention is worth only an ounce of cure? Med Decis Making 1998;18(2):141-8
   PubMed Web of Science ®Google Scholar
• Johannesson M, Johansson PO. A note on prevention versus cure. Health Policy 1997;41(3):181-7
   Google Scholar
• Mortimer D, Segal L. Is the value of a life or life-year saved context specific? Further evidence from a discrete choice experiment. Cost Eff Resour Alloc 2008;6:8
   Google Scholar
• Bosworth R, Cameron TA, DeShazo JR. Is an ounce of prevention worth a pound of cure? Comparing demand for public prevention and treatment policies. Med Decis Making 2010;30(4):E40-56
   PubMed Web of Science ®Google Scholar
• Meertens RM, Van de Gaar VMJ, Spronken M, de Vries NK. Prevention praised, cure preferred: results of between-subjects experimental studies comparing (monetary) appreciation for preventive and curative interventions. BMC Med Inform Decis Mak 2013;13:136
   PubMed Web of Science ®Google Scholar
• Broome J. Trying to value a life. J Public Econ 1978;9(1):91-100
   Google Scholar
• Dragojlovic N, Rizzardo S, Bansback N, et al. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. Patient 2015;8(1):93-101
   PubMedGoogle Scholar
• Desser AS, Olsen JA, Grepperud S. Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects. Pharmacoeconomics 2013;31(11):1051-61
   PubMedGoogle Scholar
• Claxton K, Martin S, Soares M, et al. Methods for the estimation of the nice cost effectiveness threshold [Internet]. Centre for Health Economics, University of York 2012. Available from: http://EconPapers.repec.org/RePEc:chy:respap:81cherp
   Google Scholar
• Alliance for regenerative medicine releases annual industry report showcasing impressive sector growth alliance for regenerative medicine. Internet Available from: http://alliancerm.org/press/alliance-regenerative-medicine-releases-annual-industry-report-showcasing-impressive-sector [Cited 14 February 2015]
   Google Scholar
• Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010;28(2):113-42
   PubMed Web of Science ®Google Scholar
• Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 2013;16(5):703-19
   PubMed Web of Science ®Google Scholar
• Department of health access to kalydeco through the pharmaceutical benefits scheme. Internet Available from: www.health.gov.au/internet/main/publishing.nsf/Content/MC14-000305-pharmaceutical-benefits-scheme-listing-of-kalydeco [Cited 13 February 2015]
   Google Scholar
• Edlin R, Hall P, Wallner K, McCabe C. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? Value Health 2014;17(4):438-44
   PubMed Web of Science ®Google Scholar
• Establishing new payment provisions for the high cost of curing disease. Internet AEI Available from: www.aei.org/publication/establishing-new-payment-provisions-for-the-high-cost-of-curing-disease/ [Cited 13 February 2015]
   Google Scholar
• Overview - ABOUT IFFIm - International Finance Facility for Immunisation. Internet Available from: www.iffim.org/About/Overview/ [Cited 14 February 2015]
   Google Scholar
• The Health impact fund: a summary overview incentives for global health. Internet Available from: http://healthimpactfund.org/the-health-impact-fund-a-summary-overview/ [ Cited 14 February 2015]
   Google Scholar
• Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ 2014;15(4):335-40
   PubMed Web of Science ®Google Scholar